middle.news
Neuren posts A$30m profit, advances NNZ-2591 Phase 3 and launches share buy-back
1:33pm on Friday 24th of April, 2026 AEST
•
Healthcare
Read Story
Neuren posts A$30m profit, advances NNZ-2591 Phase 3 and launches share buy-back
1:33pm on Friday 24th of April, 2026 AEST
Key Points
2025 royalty income from DAYBUE® grew 15% to A$65 million
Strong cash reserves of A$296 million support ongoing R&D
Phase 3 'Koala' trial for NNZ-2591 in Phelan-McDermid syndrome underway
Acadia’s DAYBUE STIX powder formulation launched in US, boosting growth prospects
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE